Starts & Stops: Neovasc Reports Progress On TIARA-II Trial Of Transcatheter Mitral Valve
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.
You may also be interested in...
Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock
Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.
FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.
Results Recap: Neovasc's Tiara TMVR Succeeds In 12 Patients
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition covers the week of Oct. 12 - Oct. 18, including trial announcements from PositiveID, Smart Meter, Access Vascular, and Neovasc.